RxDoctor Payments Data

Colin Failey, MD

Plastic and Reconstructive Surgery · Florham Park, NJNPI 1992957922

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $35,794 of the $39,826 with a category attached, or 89.9%. 13 manufacturers reported payments, led by Revance Therapeutics, Inc. at 53.6% of the total. 2025 is the largest year on record at $25,830, more than ten times the $266 reported in 2019. Among plastic and reconstructive surgery clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,826in general payments, 2019–2025

Across 204 payments — averaging $195.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Revance Therapeutics, Inc.$21K
  • AbbVie$15K
  • RTI Surgical, Inc$2K
  • Musculoskeletal Transplant Foundation Inc.$293
  • Sientra, Inc.$286
  • Motiva USA, LLC$83
  • plus $176 from 7 others

What the payments were for

  • Speaking & faculty fees$35,79490%
  • Travel & lodging$470%
  • Food & beverage$3,98610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,826 in reported general payments places this provider in the 95th percentile of 93 plastic and reconstructive surgery providers in New Jersey.

See all plastic and reconstructive surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$23,115
Medicare patients
27
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib11$325

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Florham Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →